CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Rare disease drug developer Egetis Q3 revenue rises on EMCITATE sales

By Reuters News


Overview

  • Sweden rare disease drug developer's Q3 net revenue rose 24% at CER, driven by EMCITATE sales

  • Company posted a wider Q3 net loss

  • FDA approved EMCITATE for MCT8 deficiency in the U.S. during the quarter


Outlook

  • Company prioritizes successful U.S. launch of EMCITATE in 2026

  • Company aims to optimize pricing and reimbursement and continue EMCITATE rollout in Europe

  • Egetis plans to finalize tiratricol development plan for RTH-beta in 2026


Result Drivers

  • FDA APPROVAL - EMCITATE received U.S. FDA approval for MCT8 deficiency, marking a key milestone for the company

  • COMMERCIAL LAUNCH PREPARATIONS - Co said extensive preparations enabled rapid U.S. launch of EMCITATE and early physician uptake

  • GERMANY SALES - Most Q3 EMCITATE sales came from Germany, where national reimbursement is in place


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

9M Revenue

SEK 52.30 mln

9M Adjusted Loss Per Share

SEK 0.80

9M Net Loss

SEK 350.40 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Egetis Therapeutics AB (publ) is SEK18.00, about 80.2% above its November 4 closing price of SEK9.99


Reuters Recommended Reads

  • Nov 4 - Sweden's Medicover Q3 profit rises 29% on price adjustments and wider network; to focus on Europe

  • Nov 3 - Ultragenyx Q3 revenue rises, net loss narrows

  • Nov 3 - Mirum Pharmaceuticals Q3 net product sales surge, outlook raised


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.